Kennedy Capital Management, Inc. Aldeyra Therapeutics, Inc. Transaction History
Kennedy Capital Management, Inc.
- $4.27 Billion
- Q3 2024
A detailed history of Kennedy Capital Management, Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 1,881,078 shares of ALDX stock, worth $9.29 Million. This represents 0.24% of its overall portfolio holdings.
Number of Shares
1,881,078
Previous 1,599,673
17.59%
Holding current value
$9.29 Million
Previous $5.29 Million
91.52%
% of portfolio
0.24%
Previous 0.12%
Shares
4 transactions
Others Institutions Holding ALDX
# of Institutions
117Shares Held
36.4MCall Options Held
196KPut Options Held
142K-
Perceptive Advisors LLC New York, NY9.28MShares$45.8 Million1.31% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$27 Million14.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$18.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$17.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.11MShares$5.51 Million0.0% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $288M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...